AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies

AstraZeneca jumps as tozorakimab hits primary goals in two phase III COPD trials, cuts exacerbations and shows promise in a disease with limited options. https://www.nasdaq.com/articles/azn-stock-gains-copd-drug-clears-two-late-stage-studies